Dermatology

Latest News

 Tralokinumab Dosing Every 4 Weeks is Effective Maintenance Regimen for Atopic Dermatitis / image credit ©isavira/stock.adobe.com
Tralokinumab Dosing Every 4 Weeks is Effective Maintenance Regimen for Atopic Dermatitis, Study Suggests

January 20th 2025

The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.

 New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures / image credit ©InfiniteStudio/AdobeStock
New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures

January 20th 2025

Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist
Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

January 15th 2025

 Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment  / image credit ©MichaelVI/stock.adobe.com
Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

January 13th 2025

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis / image credit ©InfiniteStudio/stock.adobe.com
Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

January 10th 2025

Latest CME Events & Activities

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Community Practice Connections™: 20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Revolutionizing Atopic Dermatitis (RAD) Conference 2025

June 6-7, 2025

Register Now!

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

View More

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

View More

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

View More

More News

© 2025 MJH Life Sciences

All rights reserved.